Holen Sie sich die Stockscreener-App
72.84
2.07%
-1.4344
Schlusskurs vom Vortag:
$74.27
Offen:
$72.56
24-Stunden-Volumen:
296.24K
Relative Volume:
0.19
Marktkapitalisierung:
$9.93B
Einnahmen:
$550.17M
Nettoeinkommen (Verlust:
$201.35M
KGV:
72.84
EPS:
1
Netto-Cashflow:
$232.07M
1W Leistung:
-1.18%
1M Leistung:
+9.57%
6M Leistung:
+10.08%
1J Leistung:
+73.70%
1-Tages-Spanne:
$71.68
$73.09
1-Wochen-Bereich:
$71.31
$75.47
52-Wochen-Spanne:
$40.87
$85.21
Doximity Inc Stock (DOCS) Company Profile
Firmenname
Doximity Inc
Sektor
Branche
Telefon
(650) 549-4330
Adresse
500 THIRD STREET, SUITE 510, SAN FRANCISCO
Vergleichen Sie DOCS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DOCS
Doximity Inc
|
72.78 | 13.84B | 550.17M | 201.35M | 232.07M | 1.00 |
|
VEEV
Veeva Systems Inc
|
276.70 | 45.70B | 2.97B | 809.93M | 1.33B | 4.87 |
|
TEM
Tempus Ai Inc
|
77.71 | 14.62B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
HQY
Healthequity Inc
|
94.92 | 8.09B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.67 | 6.58B | 906.14M | -52.62M | 89.62M | -0.3621 |
Doximity Inc Stock (DOCS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-09 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-06-02 | Hochstufung | BTIG Research | Neutral → Buy |
| 2025-02-07 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-07 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-12-20 | Eingeleitet | Stephens | Equal-Weight |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-11-15 | Eingeleitet | Goldman | Neutral |
| 2024-11-14 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2024-11-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-11-08 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-11-08 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2024-10-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-08-09 | Hochstufung | Needham | Hold → Buy |
| 2024-07-18 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2024-04-25 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2024-01-03 | Eingeleitet | Barclays | Equal Weight |
| 2024-01-02 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-08-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-08-09 | Herabstufung | Needham | Buy → Hold |
| 2023-08-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2022-10-31 | Eingeleitet | Wells Fargo | Overweight |
| 2022-10-24 | Eingeleitet | Evercore ISI | In-line |
| 2022-10-13 | Eingeleitet | BTIG Research | Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-28 | Eingeleitet | Berenberg | Buy |
| 2022-05-18 | Bestätigt | BofA Securities | Neutral |
| 2022-05-18 | Bestätigt | Goldman | Buy |
| 2022-05-18 | Bestätigt | Guggenheim | Buy |
| 2022-05-18 | Bestätigt | Jefferies | Buy |
| 2022-05-18 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-05-18 | Bestätigt | Needham | Buy |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-04 | Eingeleitet | BofA Securities | Neutral |
| 2022-02-11 | Eingeleitet | Goldman | Buy |
| 2021-12-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-11-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-10 | Bestätigt | Canaccord Genuity | Buy |
| 2021-11-10 | Bestätigt | Goldman | Neutral |
| 2021-11-10 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2021-11-10 | Bestätigt | Needham | Buy |
| 2021-11-10 | Bestätigt | Piper Sandler | Overweight |
| 2021-08-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-19 | Eingeleitet | Canaccord Genuity | Buy |
| 2021-07-19 | Eingeleitet | Goldman | Neutral |
| 2021-07-19 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-07-19 | Eingeleitet | Piper Sandler | Overweight |
| 2021-07-19 | Eingeleitet | Raymond James | Outperform |
| 2021-07-19 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-19 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Doximity Inc Aktie (DOCS) Neueste Nachrichten
Doximity, Inc. (DOCS): Among the Health Information Services Stocks Outpacing the Market in 2025 - MSN
Doximity, Inc. $DOCS Shares Sold by Riverbridge Partners LLC - MarketBeat
Strs Ohio Acquires Shares of 11,452 Doximity, Inc. $DOCS - MarketBeat
Do Options Traders Know Something About Doximity Stock We Don't? - sharewise.com
23,793 Shares in Doximity, Inc. $DOCS Purchased by Family Legacy Financial Solutions LLC - MarketBeat
Doximity (NASDAQ:DOCS) Given New $67.00 Price Target at Canaccord Genuity Group - MarketBeat
Hims & Hers Expands Care Ecosystem via Global and Digital Innovation - The Globe and Mail
Financiere des Professionnels Fonds d investissement inc. Takes $320,000 Position in Doximity, Inc. $DOCS - MarketBeat
Voya Investment Management LLC Buys 22,409 Shares of Doximity, Inc. $DOCS - MarketBeat
Doximity (NASDAQ:DOCS) Director Regina M. Benjamin Sells 5,000 Shares - MarketBeat
Gallacher Capital Management LLC Buys New Holdings in Doximity, Inc. $DOCS - MarketBeat
Doximity, Inc. $DOCS Shares Sold by Swedbank AB - MarketBeat
A Decade in Print: The Evolving Academic Benchmark of Cardiology Fellowship Applications - Cureus
Finanzdaten der Doximity Inc-Aktie (DOCS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
1.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):